Any current/future new fundraising through debt or equity?

There is no direct mention of any current or planned fundraising through debt or equity in the provided transcript. The company noted a CAPEX spend of Rs. 700 crores for the current year and acknowledged ongoing capital expenditure in the next year, but no specific mention of funding sources was given. Interest costs have come down recently, suggesting some repayment or refinancing has already taken place, but no new debt issuance was specified. No comments were made on equity issuance or raising capital through equity markets. Overall, the discussion touched on investment plans and cash flows

Any current/future capex/capital investment/strategic investment?

Sai Life Sciences is undertaking a large CAPEX of ₹700 crores for FY26. This CAPEX is based on strong visibility from existing products scaling up and late-stage pipeline projects plus clinical inquiries and collaborations. ₹700 crores CAPEX is for the current year, with CAPEX likely continuing next year though numbers are not finalized. The CAPEX covers manufacturing expansions including new production blocks (totaling around 450 KL capacity by H2 FY27) and Discovery capacity additions. Research & Development (R&D) capacity is doubling by next year, and manufacturing capacity is expected to i

Future growth expectations in sales/revenue/volumes?

Sai Life Sciences anticipates sustained growth driven by both existing and late-stage pipeline products with strong visibility from client demand (Page 15). The company targets a 3-5 year CAGR around 15% across combined CRO and CDMO businesses (Page 11). Manufacturing capacity is expected to increase by approximately 80-90% by FY'27, supporting volume growth (Page 12, 11). Process R&D capacity is planned to nearly double by next year, enhancing support for clinical and commercial supply programs (Page 3, 8). Growth will be fueled by new modalities like oligonucleotides (near commercial

Future growth expectations in earnings/operating earnings/profits/EPS?

Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth). EBITDA surged 305% YoY with margins expanding to 25%, moving towards the targeted 28%-30% margin range as revenues grow. The company is optimistic about continued growth, backed by strategic investments in capacity expansion (700 crores CAPEX this year) and new modalities like peptides, ADCs, and oligonucleotides. Management expects steady revenue growth averaging around 15% annually over the next 3-5 years. Capacity additions (~550 KL expansion by FY'27) support scal

Current/ Expected Orderbook/ Pending Orders?

The company has better visibility on order book now compared to the past, with increased confidence about utilization levels going forward. There is no specific mention of a quantified current order book value in the transcript. The capacity buildup is now more aligned with anticipated orders over the next 12-24 months, indicating strong client commitments. Late-stage pipeline visibility is strong, supported by existing forecasts, clinical inquiries, and ongoing development programs with large pharma. The company continues to onboard new large pharma customers and deepen relationships,

IN US

Sale is live|00:00:00left today

Sai Life Sciences LtdQ2 FY25Pharmaceuticals & Biotechnology

Sai Life Sciences Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,205P/E: 65.1Market Cap: ₹23.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Sai Life Sciences anticipates sustained growth driven by both existing and late-stage pipeline products with strong visibility from client demand (Page 15).
→The company targets a 3-5 year CAGR around 15% across combined CRO and CDMO businesses (Page 11).
→Manufacturing capacity is expected to increase by approximately 80-90% by FY'27, supporting volume growth (Page 12, 11).
→Process R&D capacity is planned to nearly double by next year, enhancing support for clinical and commercial supply programs (Page 3, 8).
→Growth will be fueled by new modalities like oligonucleotides (near commercial), ADCs (late-phase assets), peptides (early clinical stage), and lipids (Page 9).
→No major impact is expected from reshoring or US capacity additions on intermediates and APIs supplied by Sai (Page 15).
→Business scaling and operating leverage are expected to improve margins toward 28%-30% (Page 4).
→Overall, growth is driven by deepening client partnerships, increased scientific depth, and capacity expansions to meet evolving needs (Page 4, 15).

Margin guidance

Category 1

→Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth).
→EBITDA surged 305% YoY with margins expanding to 25%, moving towards the targeted 28%-30% margin range as revenues grow.
→The company is optimistic about continued growth, backed by strategic investments in capacity expansion (700 crores CAPEX this year) and new modalities like peptides, ADCs, and oligonucleotides.
→Management expects steady revenue growth averaging around 15% annually over the next 3-5 years.
→Capacity additions (~550 KL expansion by FY'27) support scaling for commercial and clinical supply programs, mitigating capacity constraints.
→Profits and operating earnings are expected to improve consistently due to operating leverage, scale efficiencies, and improved productivity.
→No specific EPS guidance was provided, but positive profitability trends with PAT turnaround indicate future EPS growth potential.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no direct mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company noted a CAPEX spend of Rs. 700 crores for the current year and acknowledged ongoing capital expenditure in the next year, but no specific mention of funding sources was given.
→Interest costs have come down recently, suggesting some repayment or refinancing has already taken place, but no new debt issuance was specified.
→No comments were made on equity issuance or raising capital through equity markets.
→Overall, the discussion touched on investment plans and cash flows but did not reveal any active or upcoming fundraising through debt or equity.

Order book

Yes

→The company has better visibility on order book now compared to the past, with increased confidence about utilization levels going forward.
→There is no specific mention of a quantified current order book value in the transcript.
→The capacity buildup is now more aligned with anticipated orders over the next 12-24 months, indicating strong client commitments.
→Late-stage pipeline visibility is strong, supported by existing forecasts, clinical inquiries, and ongoing development programs with large pharma.
→The company continues to onboard new large pharma customers and deepen relationships, enhancing order book quality.
→The CDMO business remains lumpy and volatile quarter-on-quarter, but growth is driven by both commercialized and existing molecules.
→Despite volatility, no one-offs or stock build-ups affecting order flow were reported in Q1 FY'26.

Capex plans

Yes

→Sai Life Sciences is undertaking a large CAPEX of ₹700 crores for FY26.
→This CAPEX is based on strong visibility from existing products scaling up and late-stage pipeline projects plus clinical inquiries and collaborations.
→₹700 crores CAPEX is for the current year, with CAPEX likely continuing next year though numbers are not finalized.
→The CAPEX covers manufacturing expansions including new production blocks (totaling around 450 KL capacity by H2 FY27) and Discovery capacity additions.
→Research & Development (R&D) capacity is doubling by next year, and manufacturing capacity is expected to increase by about 80%-90% by FY27.
→New capacity additions include 91 KL commissioned recently, 200 KL by Q3 FY27, and 450 KL expected by H2 FY27.
→Expansion also includes adding peptides and early-phase formulation capabilities.
→The company is diversifying its footprint to reduce concentration risk.

How does Sai Life Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Sai Life Sciences Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Sai Life Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio